Recent research indicated that HDAC inhibitors can enhance the efficacy of an antibody targeting CTLA-4 by modulating the relationship between immune and cancer cells, hence upregulating the recognition and elimination of tumor cells. The gene discussed is HDAC9; the disease is neoplasm.